Our scientists benefit from state-of-the-art instrumentation that enables flexible, customer-focused assay development and the acquisition of up to 400,000 data points per day in a 1,536-well format. The processing of the data volume is managed by cutting-edge data management systems (Genedata Screener; PerkinElmer Spotfire), enabling the best possible processing and provision of data to customers.
The NUVISAN screening team has extensive assay and screening expertise covering a wide range of target classes and mechanisms:
The screening cascade of an HTS project is custom tailored for every project. After identifying hits in the 3-million-compound library for the primary target assay, hit confirmation ensures that those hits are specific to the target and do not interfere with the detection system. Dose-response analysis in selectivity, biophysical, and cell-based assays, as well as LC-MS data, enable the selection of desired compound profiles for the validated hit list. Additional assessments from our MedChem experts and data from our Life Science Database support the selection process. On the way to the licensed hits, re-synthesis of selected cluster members and additional assays increase the confidence, creating a successful follow-up hit-to-lead program.
Panknin, O., et al., Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women. J Med Chem (2020)